160 related articles for article (PubMed ID: 35030282)
21. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Molica S; Giannarelli D; Mirabelli R; Levato L; Russo A; Linardi M; Gentile M; Morabito F
Eur J Haematol; 2016 Jan; 96(1):72-7. PubMed ID: 25819739
[TBL] [Abstract][Full Text] [Related]
22. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia.
González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Sanzo C; Aventín A; Puiggros A; Collado R; Heras C; Muñoz C; Delgado J; Ortega M; González MT; Marugán I; de la Fuente I; Recio I; Bosch F; Espinet B; González M; Hernández-Rivas JM; Hernández JÁ; ;
Hematol Oncol; 2016 Jun; 34(2):84-92. PubMed ID: 25689772
[TBL] [Abstract][Full Text] [Related]
23. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
25. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
[TBL] [Abstract][Full Text] [Related]
26. Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study.
Nørgaard CH; Søgaard NB; Biccler JL; Pilgaard L; Eskesen MH; Kjartansdottir TH; Bøgsted M; El-Galaly TC
PLoS One; 2018; 13(12):e0208180. PubMed ID: 30589850
[TBL] [Abstract][Full Text] [Related]
27. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Wierda WG; O'Brien S; Wang X; Faderl S; Ferrajoli A; Do KA; Garcia-Manero G; Cortes J; Thomas D; Koller CA; Burger JA; Lerner S; Schlette E; Abruzzo L; Kantarjian HM; Keating MJ
J Clin Oncol; 2011 Nov; 29(31):4088-95. PubMed ID: 21969505
[TBL] [Abstract][Full Text] [Related]
28. Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
Galieni P; Troiani E; Picardi P; Angelini M; Mestichelli F; Dalsass A; Maravalle D; Camaioni E; Bigazzi C; Caraffa P; Ruggieri M; Mazzotta S; Mattioli S; Angelini S
Leuk Res; 2024 Jun; 143():107541. PubMed ID: 38905908
[TBL] [Abstract][Full Text] [Related]
29. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
[TBL] [Abstract][Full Text] [Related]
30. Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia.
Alshemmari SH; Almazyad M; Alsarraf A; Kunhikrishnan A; Isaac AM; Kaempf A
Hematol Oncol Stem Cell Ther; 2024 Mar; 17(2):137-145. PubMed ID: 38560969
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
Amaya-Chanaga CI; Rassenti LZ
Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].
Zhu HY; Wang L; Qiao J; Zou YX; Xia Y; Wu W; Cao L; Liang JH; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):392-397. PubMed ID: 29779348
[No Abstract] [Full Text] [Related]
34. Expression of BCL11A in chronic lymphocytic leukaemia.
Tosic N; Ugrin M; Marjanovic I; Kostic T; Vukovic V; Tomic K; Otasevic V; Antic D; Mihaljevic B; Pavlovic S; Karan-Djurasevic T
Int J Lab Hematol; 2023 Feb; 45(1):64-71. PubMed ID: 36120992
[TBL] [Abstract][Full Text] [Related]
35. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
Van Dyke DL; Werner L; Rassenti LZ; Neuberg D; Ghia E; Heerema NA; Dal Cin P; Dell Aquila M; Sreekantaiah C; Greaves AW; Kipps TJ; Kay NE
Br J Haematol; 2016 Apr; 173(1):105-13. PubMed ID: 26848054
[TBL] [Abstract][Full Text] [Related]
36. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P; Giza A; Robrecht S; Cramer P; von Tresckow J; Al-Sawaf O; Fink AM; Fürstenau M; Kutsch N; Simon F; Goede V; Hoechstetter M; Niemann CU; da Cunha-Bang C; Kater A; Dubois J; Gregor M; Staber PB; Tausch E; Schneider C; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M
Blood; 2024 Jun; 143(25):2588-2598. PubMed ID: 38620092
[TBL] [Abstract][Full Text] [Related]
37. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.
Muñoz-Novas C; Poza-Santaella M; González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Infante MS; Heras C; Foncillas MÁ; Marín K; Hernández-Rivas JM; Hernández JÁ
Biomed Res Int; 2018; 2018():9506979. PubMed ID: 29736400
[TBL] [Abstract][Full Text] [Related]
38. Diabetes Mellitus Is Associated with Inferior Prognosis in Patients with Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis.
Gao R; Man TS; Liang JH; Wang L; Zhu HY; Wu W; Fan L; Li JY; Yang T; Xu W
Cancer Res Treat; 2020 Jan; 52(1):189-206. PubMed ID: 31291713
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors for Chronic Lymphocytic Leukemia.
Chen C; Puvvada S
Curr Hematol Malig Rep; 2016 Feb; 11(1):37-42. PubMed ID: 26748932
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
Cherng HJ; Jammal N; Paul S; Wang X; Sasaki K; Thompson P; Burger J; Ferrajoli A; Estrov Z; O'Brien S; Keating M; Wierda WG; Jain N
Br J Haematol; 2021 Jul; 194(1):61-68. PubMed ID: 33973230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
